The experimental drug lecanemab is being hailed as a major breakthrough as an Alzheimer’s disease treatment, according to new Phase 3 trial results. Lecanemab has become one of the first experimental dementia drugs to show promising results in slowing the progression of cognitive decline. The trial data was published Tuesday…
